11/01/2024
Today, the University of Copenhagen shared the positive results of an investigational study, published in Blood providing ground-breaking evidence that Staphylococcus aureus and its toxins induce drug resistance in malignant T-cells against therapeutics such as HDAC inhibitors and chemotherapies commonly used for cutaneous T cell lymphoma (CTCL). Importantly, the study shows that bacterial killing by Micreos engineered, S. aureus-targeting endolysin countered this drug-resistance effect.
Read More07/03/2023
Research shows XZ.700* could block tumor promoting effects of S. aureus on malignant T cells, potentially delaying tumor progression.
Read More25/10/2022
Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.
Read More14/04/2022
Zug, Switzerland, 14 April 2022 — Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of XZ.700, a novel antibacterial enzyme, in selectively targeting and killing the harmful Staphylococcus aureus bacterial pathogen while maintaining a healthy microbiome and preventing antimicrobial resistance (AMR).
Read More05/04/2022
Zug, Switzerland, 5-April 2022 — Micreos Pharmaceuticals today announces the expansion of its leadership team to include Trine Ahlgreen as Chief Business Officer and Carsten Edwards as Chief Development Officer.
Read More14/10/2021
The Hague, October 14, 2021 - Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland.
Read More30/09/2021
THE HAGUE, The Netherlands, 30 September, 2021 - Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria.
Read More22/09/2020
The Hague, 22 September 2020, Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.
Read More